Pricing

MEI Pharma Inc (MEIP)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Daniel P. Gold
Employees:
100
11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130
858-369-7100
    Formally known as:
  • Marshall Edwards Inc.
Stock Split History
DateRatio
2010-03-31 1:1
2012-12-19 1:6
2023-04-17 1:20
MEI Pharma, Inc. focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trials for patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex in Phase I clinical trial for human epidermal growth factor receptor 2 negative breast cancer.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available